A 52-year-old male with a past medical history of hypertension presented with a two-week history of mild right lower quadrant abdominal pain. He denied chronic non-steroid anti-inflammatory drug use, alcohol or tobacco abuse. No skin lesions or any areas of hypo/hyperpigmentation were noted. Abdominal exam revealed mild tenderness in the right lower quadrant. Laboratory data including serum sodium, potassium, creatinine and blood urea nitrogen were normal. Other normal tests included liver function tests, lipase and thyroid stimulating hormone levels. Urine analysis was negative. A colonoscopy was performed which showed three sessile 3 mm polyps in the splenic flexure and proximal descending colon ([Fig. 1](#F1){ref-type="fig"}). Polypectomy was performed and histology examination showed a thickened lamina propria arranged in a fascicular-like pattern wrapped around dispersed benign colonic glands. Immunohistochemical staining with S-100 confirmed the diagnosis of colonic neurofibroma ([Fig. 2](#F2){ref-type="fig"}).

![(A) Narrow band imaging showing sessile polyps in the proximal descending colon. (B) Colonoscopy with white light showing sessile polyps in the splenic flexure](AnnGastroenterol-29-381-g001){#F1}

![(A) Low magnification (20 x). H & E stain. Specimen showing unremarkable large bowel glands separated by a thickened lamina propria. (B) Low magnification (20 x), S-100 stain. The cells of the lamina propria are positive for S-100 immunohistochemical stain, indicating a neurofibroma](AnnGastroenterol-29-381-g002){#F2}

Isolated neurofibroma of the gastrointestinal tract was first described in 1937, and remains a rare entity \[[@ref1]\]. Since then, less than 20 such cases have been reported in the literature \[[@ref2]\]. Clinical presentation ranges from incidental findings on routine colonoscopy to massive lower gastrointestinal bleeding \[[@ref2],[@ref3]\]. In spite of an increase in reporting of isolated colonic neurofibromas (ICN) in the past decade, the etiology, pathogenesis, prognosis and treatment options for ICN remain unclear. In addition, there are no data on the need for follow-up colonoscopies and the appropriate intervals.

This and other cases highlight the importance of close follow up and detailed skin exams in these patient populations to monitor for any signs of systemic neurofibromatosis. It also raises the need for a consensus guideline on follow-up care in patients with ICN including intervals for surveillance colonoscopies.
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